定量药理和药物经济学联合模型在药物研发与评价中的应用

陈蕊, 柴青青, 刘晓芹, 焦正

中国药学杂志 ›› 2023, Vol. 58 ›› Issue (19) : 1795-1800.

PDF(1161 KB)
中国药学杂志
PDF(1161 KB)
中国药学杂志 ›› 2023, Vol. 58 ›› Issue (19) : 1795-1800. DOI: 10.11669/cpj.2023.19.011
论著

定量药理和药物经济学联合模型在药物研发与评价中的应用

  • 陈蕊, 柴青青, 刘晓芹, 焦正*
作者信息 +

Pharmacometrics-Pharmacoeconomics Model in Drug Development and Drug Assessment

  • CHEN Rui, CHAI Qingqing, LIU Xiaoqin, JIAO Zheng*
Author information +
文章历史 +

摘要

目的 探讨定量药理学和药物经济学(PMPE)联合模型在药物生命周期中的应用。方法 在PubMed、EMBASE以及the Cochrane Library数据库检索PMPE联合模型在药物研发中的应用。结果 共获取12篇文献,报道了PMPE联合模型在药物早期研发决策、临床试验设计优化,药品合理定价等药物研发阶段的应用,以及在药物上市后仿制药的上市决策和临床精准用药方面发挥的重要作用。结论 PMPE联合模型有助于整个药物生命周期的经济学评价,为药物研发及药物资源的合理利用提供参考。

Abstract

OBJECTIVE To explore the application of the pharmacometrics-pharmacoeconomics (PMPE) model in the drug lifecycle. METHODS A systematic literature search of PubMed, EMBASE, and Cochrane Library databases for the application in drug research and development of PMPE model was conducted. RESULTS A total of 12 literatures were obtained, which reported the application of PMPE model in drug research and development stage, such as early-stage research and development decision, optimization of clinical trial design, and rational drug pricing, as well as the important role it plays in the post-market approval of generic drugs and clinical accurate drug. CONCLUSION The PMPE model is helpful to the development of economic evaluation in the entire drug lifecycle, which may provide a reference for the development of drug and the rational use of drug resources.

关键词

定量药理学 / 药物经济学 / 药物研发 / 药品评价 / 模型

Key words

pharmacometrics / pharmacoeconomics / drug research and development / drug assessment, model

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
陈蕊, 柴青青, 刘晓芹, 焦正. 定量药理和药物经济学联合模型在药物研发与评价中的应用[J]. 中国药学杂志, 2023, 58(19): 1795-1800 https://doi.org/10.11669/cpj.2023.19.011
CHEN Rui, CHAI Qingqing, LIU Xiaoqin, JIAO Zheng. Pharmacometrics-Pharmacoeconomics Model in Drug Development and Drug Assessment[J]. Chinese Pharmaceutical Journal, 2023, 58(19): 1795-1800 https://doi.org/10.11669/cpj.2023.19.011
中图分类号： R95   

参考文献

[1] LIU C Y, LIU G X. Pharmacoeconomics: evaluation and application. China J Pharm Econ(中国药物经济学), 2019, 14(2): 122-128.
[2] WANG L T, PENG L B, PENG Y, et al. Comparative analysis between 2020 version and 2011 version on China guidelines for pharmacoeconomic evaluation. China J Pharm Econ(中国药物经济学), 2021, 16(3): 5-8,15.
[3] GUAN H J, YUE X M, WU J H, et al. Applications and challenges of guidelines for pharmacoeconomic evaluation in China. Chin Pharm J(中国药学杂志), 2017, 52(13):1188-1193.
[4] HUGHES D A. Pharmacoeconomics. Br J Clin Pharmacol, 2012, 73(6):968-972.
[5] LIU D Y, WANG K, MA G L, et al.The value and general consideration of pharmacometric study in new drug development. Chin J Clin Pharmacol Ther(中国临床药理学与治疗学), 2018, 23(9): 961-973.
[6] WANG Y, ZHU H, MADABUSHI R, et al. Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther, 2019, 105(4): 899-911.
[7] HUGHES D A, WALLEY T. Economic evaluations during early (phase Ⅱ) drug development: a role for clinical trial simulations?. Pharmacoeconomics, 2001, 19(11): 1069-1077.
[8] RICE D P. Estimating the cost of illness. Am J Public Health Nations Health, 1967, 57(3): 424-440.
[9] SCHOENBAUM S C. Cost effectiveness considerations in clinical trials. Triangle, 1980, 19(3):103-106.
[10] PAUL M. Role of pharmacoeconomic analysis in R&D decision making: when, where, how?. Pharmacoeconomics, 2005, 23(1): 1-12.
[11] YAN J Z, DONG X Y, MA X F, et al. The UK value-based pricing concept and its enlightenment on China′s medical insurance drug reimbursement policy. Chin J Health Policy (中国卫生政策研究), 2020, 13(1): 62-69.
[12] CLEMENS K, GARRISON L P, JONES A, et al. Strategic use of pharmacoeconomic research in early drug development and global pricing. Pharmacoeconomics, 1993, 4(5): 315-322
[13] MAUSKOPF J, SCHULMAN K, BELL L, et al. A strategy for collecting pharmacoeconomic data during phase Ⅱ/Ⅲ clinical trials. Pharmacoeconomics, 1996, 9(3): 264-277.
[14] SCULPHER M, DRUMMOND M, BUXTON M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy, 1997, 2(1): 26-30.
[15] GRABOWSKI H. The effect of pharmacoeconomics on company research and development decisions. Pharmacoeconomics, 1997, 11(5): 389-397.
[16] YAN W. A review of pharmacoeconomic analysis methods. China J Pharm Econ (中国药物经济学), 2017, 12(1):16-17, 37.
[17] MOULD D, UPTON R. Basic concepts in population modeling, simulation, and model-based drug development . CPT Pharmacomet Syst Pharmacol, 2012, 1(9): e6. DOI:10.1038.psp.2013.71.
[18] SRINIVASAN M, WHITE A, CHATURVEDULA A, et al. Incorporating pharmacometrics into pharmacoeconomic models: applications from drug development. Pharmacoeconomics, 2020, 38(10): 1031-1042.
[19] POLAND B, WADA R. Combining drug-disease and economic modelling to inform drug development decisions. Drug Discov Today, 2001, 6(22): 1165-1170.
[20] PINK J, LANE S, HUGHES D A. Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma. Pharmacoeconomics, 2012, 30(5): 413-429.
[21] VAN HASSELT J G, GUPTA A, HUSSEIN Z, et al. Integrated simulation framework for toxicity, dose intensity, disease progression, and cost effectiveness for castration-resistant prostate cancer treatment with eribulin. CPT Pharmacomet Syst Pharmacol, 2015, 4(7): 374-385.
[22] SLEJKO J F, WILLKE R J, RIBBING J, et al. Translating pharmacometrics to a pharmacoeconomic model of COPD. Value Health, 2016, 19(8): 1026-1032.
[23] HILL-MCMANUS D, MARSHALL S, SOTO E, et al. Impact of non-adherence and flare resolution on the cost-effectiveness of treatments for gout: application of a linked pharmacometric/pharmacoeconomic model. Value Health, 2018, 21(12): 1373-1381.
[24] HILL-MCMANUS D, MARSHALL S, SOTO E, et al. Integration of pharmacometrics and pharmacoeconomics to quantify the value of improved forgiveness to nonadherence: a case study of novel xanthine oxidase inhibitors for gout. Clin Pharmacol Ther, 2019, 106(3): 652-660.
[25] PINK J, PIRMOHAMED M, LANE S, et al. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther, 2014, 95(2): 199-207.
[26] IANNAZZO S, CORTESI P A, CREA R, et al. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. Blood Coagul Fibrinolysis, 2017, 28(6): 425-430.
[27] KAMAL M A, SMITH P F, CHAIYAKUNAPRUK N, et al. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. Br J Clin Pharmacol, 2017, 83(7): 1580-1594.
[28] WANG C Y, PHAM P N, KIM S, et al. Predicting cost-effectiveness of generic vs. brand dabigatran using pharmacometric estimates among patients with atrial fibrillation in the United States. Clin Transl Sci, 2020, 13(2): 352-361.
[29] PIENA M A, HOUWING N, KRAAN C W, et al. An Integrated pharmacokinetic- pharmacodynamic-pharmacoeconomic modeling method to evaluate treatments for adults with schizophrenia. Pharmacoeconomics, 2022, 40(1):121-131.
[30] US Food Drug Administration. US Department of Health Human Services. Challenge and opportunity on the critical path to new medical technologies. March 2004. Available from: https://www.who.int/intellectualproperty/documents/en/FDAproposals.pdf.
[31] National Institute for Health and Care Excellence. Lesinuracl for treating Chronic Hyperuricaem in people with gout. . http://www.nice.org.uk/guidance/tas06.
[32] CHEN C X, ZHENG B, ZHENG H R, et al. Evaluation of systematic evaluation of economics of generic drugs through the quality and efficacy consistency of generic drugs. China J Pharm Econ (中国药物经济学), 2020, 15(7): 10-19.
[33] MILLIGAN P A, BROWN M J, MARCHANT B, et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther, 2013, 93(6): 502-514.
[34] GRUTTERS J P C, GOVERS T, NIJBOER J, et al. Problems and promises of health technologies: the role of early health economic modeling. Int J Health Policy, 2019, 8(10): 575-582.
PDF(1161 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉